WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

Alterations in ATCvet codes

 Alterations included in the ATCvet Index valid from 2021

Previous ATCvet codeATCvet level name New ATCvet code
QJ05AX08raltegravirQJ05AJ01
QJ05AX11elvitegravirQJ05AJ02
QJ05AX12dolutegravirQJ05AJ03
QL01XEProtein kinase inhibitorsDeleted
QL01XE01imatinibQL01EA01
QL01XE02gefitinibQL01EB01
QL01XE03erlotinibQL01EB02
QL01XE04sunitinibQL01EX01
QL01XE05sorafenibQL01EX02
QL01XE06dasatinibQL01EA02
QL01XE07lapatinibQL01EH01
QL01XE08nilotinibQL01EA03
QL01XE09temsirolimusQL01EG01
QL01XE10everolimusQL01EG02
QL01XE11pazopanibQL01EX03
QL01XE12vandetanibQL01EX04
QL01XE13afatinibQL01EB03
QL01XE14bosutinibQL01EA04
QL01XE15vemurafenibQL01EC01
QL01XE16crizotinib QL01ED01
QL01XE17axitinibQL01EK01
QL01XE18ruxolitinibQL01EJ01
QL01XE19ridaforolimusQL01EG03
QL01XE21regorafenibQL01EX05
QL01XE22masitinibQL01EX06
QL01XE23dabrafenibQL01EC02
QL01XE24ponatinibQL01EA05
QL01XE25trametinibQL01EE01
QL01XE26cabozantinibQL01EX07
QL01XE27ibrutinibQL01EL01
QL01XE28ceritinibQL01ED02
QL01XE29lenvatinibQL01EX08
QL01XE31nintedanibQL01EX09
QL01XE32cediranibQL01EK02
QL01XE33palbociclibQL01EF01
QL01XE34tivozanibQL01EK03
QL01XE35osimertinibQL01EB04
QL01XE36alectinibQL01ED03
QL01XE37rociletinibQL01EB05
QL01XE38cobimetinibQL01EE02
QL01XE39midostaurinQL01EX10
QL01XE40olmutinibQL01EB06
QL01XE41binimetinibQL01EE03
QL01XE42ribociclibQL01EF02
QL01XE43brigatinibQL01ED04
QL01XE44lorlatinibQL01ED05
QL01XE45neratinibQL01EH02
QL01XE46encorafenibQL01EC03
QL01XE47dacomitinibQL01EB07
QL01XE48icotinibQL01EB08
QL01XE50abemaciclibQL01EF03
QL01XE51acalabrutinibQL01EL02
QL01XE52quizartinibQL01EX11
QL01XE53larotrectinibQL01EX12
QL01XE54gilteritinibQL01EX13
QL01XE56entrectinibQL01EX14
QL01XE57fedratinibQL01EJ02
QL01XE91toceranibQL01EX90
QL01XX14tretinoinQL01XF01
QL01XX17topotecanQL01CE01
QL01XX19irinotecanQL01CE02
QL01XX22alitretinoinQL01XF02
QL01XX25bexaroteneQL01XF03
QL01XX32bortezomibQL01XG01
QL01XX38vorinostatQL01XH01
QL01XX39romidepsinQL01XH02
QL01XX42panobinostatQL01XH03
QL01XX43vismodegibQL01XJ01
QL01XX45carfilzomibQL01XG02
QL01XX46olaparibQL01XK01
QL01XX47idelalisibQL01EM01
QL01XX48sonidegibQL01XJ02
QL01XX49belinostatQL01XH04
QL01XX50ixazomib QL01XG03
QL01XX54niraparib QL01XK02
QL01XX55rucaparib QL01XK03
QL01XX56etirinotecan pegol QL01CE03
QL01XX60talazoparibQL01XK04
QL01XX61copanlisibQL01EM02
QL01XX63glasdegibQL01XJ03
QL01XX64entinostatQL01XH05
QL01XX65alpelisibQL01EM03
QL01XX68belotecanQL01CE04

Other alterations in ATCvet 2021

Alterations included in the ATCvet Index valid from 2021

ATCvet codePrevious ATCvet level name New ATCvet level name or new ATCvet level
QC10BAHMG CoA reductase inhibitors in combination with other lipid modifying agentsCombinations of various lipid modifying agents
QC10BXHMG CoA reductase inhibitors, other combinationsLipid modifying agents in combination with other drugs

Last updated: 2021-01-26